Prevalence of factor V Leiden and prothrombin G20210A gene mutation

Saudi Medical Journal

Volumn 26, Issue 4, 2005, Pages 580-583

  Irdem, Ahmet ^a   Devecioglu, Celal ^a   Batun, Sabri ^a   Soker, Murat ^a   Sucakli, Iclal A ^a  

^a DICLE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; BLOOD CLOTTING FACTOR 5 LEIDEN; DNA; EDETIC ACID; GLYCINE; ORAL CONTRACEPTIVE AGENT; PROTEIN C; PROTHROMBIN;

ACTIVATED PROTEIN C RESISTANCE; ADOLESCENT; ANALYTICAL EQUIPMENT; ARTICLE; BLOOD SAMPLING; CAPILLARY; CAUCASIAN; CHILD; CONTROLLED STUDY; CORRELATION FUNCTION; DNA ISOLATION; FAMILY HISTORY; FEMALE; FREQUENCY ANALYSIS; GENE IDENTIFICATION; GENE MUTATION; HETEROZYGOTE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; MEDICAL SCHOOL; OUTPATIENT DEPARTMENT; PEDIATRIC HOSPITAL; PERIPHERAL VEIN; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; PREGNANCY; PREOPERATIVE EVALUATION; PREVALENCE; RELATIVE; RISK FACTOR; TUBE; TURKEY (REPUBLIC); UNIVERSITY; VEIN THROMBOSIS; VENOUS BLOOD;

FACTOR V; FEMALE; HUMANS; MALE; MUTATION; PREVALENCE; PROTHROMBIN;

EID: 19044364846     PISSN: 03795284     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Ozyurek HE, Gurgey A. The hereditary factors that cause Thrombosis. Katkι Pediatr 2001; 22: 170-177.
2. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369; 64-67.
3. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-3703.
4. Rees DC, Cox Clegg JB. World distribution of faktor V Leiden. Lancet 1995; 346: 1133-1134.
5. Gurgey A, Mesci L. The prevalence of factor V Leiden (1691 G-A) mutation in Turkey. Turk J Pediatr 1997; 39: 313-315.
6. Ozbek U, Tangun Y. Frequency of factor V Leiden (Arg506Gln) in Turkey. Br J Hematol 1997; 97: 504-505.
7. Herrmann FH, Koesling M, Schroder W, Altman R, Jimenez Bonilla R, Lopaciuk S, et al. Prevalence of factor V Leiden mutation in various populations. Genet Epidemiology 1997; 14: 403-411.
8. Pecheniuk NM, March NA, Walsh NA, Dale JL. Use of first nucleotide change technology to determine the frequency of factor V Leiden in a population of Australian blood donors. Blood Coagulation Fibrinolysis 1997: 8: 491-495.
9. Garcia-Gala JM, Alvarez V, Pinto CR, Soto I, Urgelles MF, Menender MJ, et al. Faktor V Leiden (R506Q) and risk of venous thromboembolism: a case-control study based or the Spanish population. Clin Genet 1997; 52: 206-210.
10. Ridker PM, Miletich JP, Hennekens CH, Buring JE. Ethnic distribution of factor V Leiden in 4047 men and women. JAMA 1997; 277: 1305-1307.
11. Takamiya O, Ishada F, Kodaira H, Kitano K. APC-resistance and Mnl genotype (Gln 506) of coagulation factor V are rare in Japanese population. Thromb Haemost 1995; 74: 996-1002.
12. de Maat MPM, Kluft C, Jespersen J, Gram J. World distribution of factor V Leiden mutation. Lancet 1996: 347: 58.
13. Fujimura H, Kambayashi J, Monden M, Kato H, Miyata T. Coagulation faktor V Leiden mutation may have a racial background. Thromb Haemost 1996; 74: 1381-1382.
14. Dahlback B. Resistance to activated protein C caused by factor V R506Q mutation is a common risk factor for venous thrombosis. Thromb Haemost 1997; 78: 483-488.
15. Gurgey A. Hiçsönmez G, Parlak H, Balta G, Celiker A. PG20210A mutation in Turkish Patients with Thrombosis. Am J Hematology 1998; 59: 179-180
16. Akar N, Misirlioglu M, Akar E, Avcu F, Yalcin A, Sozuoz A. Prothrombin gene 20210 G-A mutation in the Turkish population. Am J Hematol 1998; 58: 249.
17. Lay MJ, Wittwer CT. Real-time fluorescence genotyping of factor V Leiden during rapid-cycle PCR. Clinical Chemistry 1997; 43: 2262-2267.
18. Nauch M, Marz W, Wieland H. Evaluation of the Roche Diagnostics Light Cycler-FVL Mutation Detection Kit and the Light Cycler-Prothrombin Mutation Detection Kit. Clinical Biochemistry 2000; 33: 213-216.
19. Emmerich J, Rosendaal FR, Cattaneo M, Margaglione M, De Stefano V, Cumming T, et al. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism - pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism. Thromb Haemost 2001; 86: 809-816.
20. Grandone E, Margaglione M, Colaizzo D, Pavone G, Paladini D, Martinelli P, et al. Lower birth-weight in neonates of mothers carrying factor V G1691A and factor IIA(20210) mutations. Haematologica 2002; 87: 177-181.
21. Pipe SW, Schmaier AH, Nichols WC, Ginsburg D, Bozynski ME, Castle VP. Neonatal purpura fulminans in association with factor V R506Q mutation. J Pediatr 1996; 128: 706-709.
22. Nowak-Gottl U, Binder M, Dubbers A, Kehrel B, Koch HG, Veltmann H, et al. Arg506 to Gln mutation in the factor V gene causes poor fibrinolytic response in children after venous occlusion. Thromb Haemost 1997; 78: 1115-1118.
23. Martinelli I, Landi G, Merati G, Cella R, Tosetto A, Mannucci PM. Factor V gene mutation is a risk factor for cerebral venous thrombosis. Thromb Haemost 1996; 75: 393-394.
24. Zuber M, Toulon P, Marnet L, Mas JL. Factor V Leiden mutation in cerebral venous thrombosis. Stroke 1996; 27: 1721-1723.
25. Hunt BJ. Activated protein C and retinal vein occlusion. Br J Ophthalmol 1996; 80: 194.
26. Larsson J, Olafsdottir E, Bauer B. Activated protein C resistance in young adults with central retinal vein occlusion. Br J Ophthalmol 1996; 80: 200-202.
27. Larsen TB, Norgaard-Pedersen B, Lundemose JB, Rudiger N, Gaustadnes M, Brandslund I. Sudden infant death syndrome, childhood thrombosis, and presence of genetic risk factors for thrombosis. Thromb Res 2000; 98: 233-239.
28. Mercuri E, Cowan F, Gupte G, Manning R, Laffan M, Rutherford M. Prothrombic disorders and abnormal neurodevelopmental outcome in infants with neonatal cerebral infarction. Pediatrics 2001; 107: 1400-1404.
29. Verity DH, Vaughan RW, Madanat W, Kondeatis E, Zureikat H, Fayyad F, et al. Factor V Leiden mutation is associated with ocular involvement in Behcet disease. Am J Ophthalmol 1999; 128: 352-356.
30. Akar N, Akar E, Dalgin G, Sözüöz A, Ömürlü K, Cin S. Frequency of Factor V (1691 G-A) Mutation in Turkish Population. Thromb Haemost 1997; 78: 1527-1528.
31. Gul A, Ozbek U, Oztürk C, Inanç M, Koniçe M, Ozçelik T. Coagulation Factor V Gene Mutation increases the risk of venous thrombosis in Behçet's Disease. Br J Rheumatology 1996: 35: 1178-1180.
32. Irani-Hakime N, Tamim H, Kreidy R, Almawi YW. The prevalence of factor V R506Q mutation-Leiden among apparently healthy Lebanese. Am J Hematology 2000; 65: 45-49.
33. Schroder W, Koesling M, Wulff K, Wehnert M, Herrmann FH. Large-scale screening for factor V Leiden mutation in north-eastern German population. Haemostasis 1996; 26: 233-236.
34. Awidi A, Shannak M, Bseiso A, Kailani MA, Anshasi B, Omar N, et al. High prevalence of factor V Leiden in healthy Jordanian Arabs. Thromb Haemost 1999; 81: 582-584.
35. Zoller B, Norlund L, Leksell H, Nilsson JE, von Schenck H, Rosen U, et al. High Prevalence of the FVR506Q mutation causing APC resistance in a region of southern Sweden with a high incidence of venous thrombosis. Thromb Res 1996; 83: 475-477.
36. Angchaisuksiri P, Pingsuthiwong S, Aryuchai K, Busabaratana M, Sura T, Atichartakarn V, et al. Prevalence of the G1691A mutation in the factor V gene (factor V Leiden) and the G20210A prothrombin gene mutation in the Thai population. Am J Hematol 2000; 65: 119-122.
37. Gurgey A, Kudayarov DK, Tuncer M, Parlak H, Altay C. The factor V Leiden and prothrombin G20210A mutations in Kirghiz population. Thromb Haemost 2000; 84: 356.
38. Togrul J, Rustamov R, Gurgey A, Altay S, Altay C. Prevalence of the prothrombin gene G20210A mutation in Azerbaijan. Br J Haematol 2000; 108: 887-888.
39. Antoniadi T, Hatzis T, Kroupis C, Economou-Petersen E, Petersen MB. Prevalence of factor V Leiden, prothrombin G20210A, and MTHFR C677T mutations in a Greek population of blood donors. Am J Hematol 1999; 61: 265-267.
40. Hepner M, Roldan A, Pieroni G, Frontroth JP, Serviddio RM, Torres AF, et al. Factor V Leiden mutation in the Argentinean population. Thromb Haemost 1999; 81: 989.
41. Balogh I, Poka R, Pfliegler G, Dekany M, Boda Z, Muszbek L. High prevalence of factor V Leiden mutation and 20210A prothrombin variant in Hungary. Thromb Haemost 1999; 81: 660-661.
42. Adamczuk Y, Iglesias Varela ML, Forastiero R, Martinuzzo M, Cerrato G, Pombo G, et al. Factor V Leiden and prothrombin G20210A variant are risk factors for venous thromboembolism in the Argentinean population. Thromb Haemost 2000; 83: 509-510.
43. Rosendaal FR, Doggen CJ, Zivelin A, Arruda VR, Aiach M, Siscovick DS, et al. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost 1998; 79: 706-708.
44. Ayyildiz O, Kalkanli S, Batun S, Aybak M, Isikdogan A, Tiftik N et al. Prothrombin G20210A gene mutation with light cycler polymerase chain reaction in venous thrombosis and healthy population in the southeast of Turkey. Heart Vessels 2004 (in press).